Levetiracetam Stragen

Levetiracetam, the active ingredient in Levetiracetam Stragen, is an anticonvulsant presented as an intravenous solution for intravenous use. It is employed to manage various seizure types in patients with epilepsy, working by modulating neuronal activity to reduce seizure frequency and severity across different seizure classifications.

GNH USA supplies Levetiracetam Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company ensures quality manufacturing, regulatory compliance, and reliable distribution to healthcare facilities across global markets.

Levetiracetam is an anticonvulsant indicated for several seizure disorders.

- Partial‑onset seizures: reduces frequency of focal seizures in patients with epilepsy. - Generalized tonic‑clonic seizures: helps control convulsive episodes in generalized epilepsy. - Myoclonic seizures: decreases rapid, involuntary muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: heightened emotional responsiveness. - Depression: low mood or loss of interest.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare but serious skin disorder. - Suicidal thoughts: emergence of depressive ideation or self‑harm urges. - Severe skin rash: extensive erythema or blistering. - Blood disorders: neutropenia or thrombocytopenia. - Multi‑organ hypersensitivity: systemic inflammatory response affecting multiple organs.

When prescribing Levetiracetam Stragen, consider the following precautions.

- Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests during therapy. - Pregnancy: use only if potential benefit justifies potential risk (Category C). - Mood changes: observe for signs of depression, irritability, or suicidal thoughts. - Concomitant antiepileptic drugs: assess for additive central nervous system effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Carbamazepine: enzyme induction that lowers levetiracetam plasma concentrations. - Phenobarbital: induces metabolism, reducing levetiracetam exposure. - Phenytoin: similar induction effect leading to decreased levetiracetam levels.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam plasma concentrations. - Other antiepileptic drugs: additive central nervous system depression may require dose titration. - Oral contraceptives: levetiracetam may reduce hormonal efficacy, consider alternative contraception.